Teknisk analys av CYXONE AB OMXSTO: CYXO
Cyxone - mot miljardvärdering Redeye
DDM Holding 3 mars 2020 — A listing on Nasdaq Nordic Small Cap would provide conditions for improved liquidity in the share, increase the attention from international 19 feb. 2021 — Cyxone har inlett fas 2-studier med Rabeximod mot Covid-19. Ticker. CYXO. Nästa rapport.
Day Range. 4.85 5.19 Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. Market Cap: 278.995M: Beta (5Y Monthly) 0.40: PE Ratio (TTM) N/A: Cyxone (publ.) announced today that the first patient has been screened in the Phase 2 clinical trial of Rabeximod in Covid-19 Find out all the key statistics for Cyxone AB (CYXO.ST), including valuation measures, fiscal year financial statistics, trading record, share statistics and more. Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market.
Börslista. First North.
Karlit ska lansera flamskyddad MDF - NTT Woodnet
2020 — Cyxone är aktien där analytikerna ser största uppsidan – detta var och förbereder ett eventuellt listbyte till Nasdaq Main Market Small Cap. First North Growth Market som handelsplattform kan vi snart lämna bakom oss. Sen - Bara jag som noterade detaljen att man inte explicit skrev Small Cap denna 8 feb.
Cyxone Aktie - Dagens Industri
Where are Cyxone AB shares listed? Cyxone AB is a Sweden-based company, which is primarily focused on specialty pharmaceuticals industry. The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration.
SE0007815428. Nasdaq First North GM.
Market Cap32.62M; Shares Out58.06M; 10 Day Average Volume7,200; Dividend -; Dividend Yield-; Beta; YTD % Change19.42. Show Ratios / Profitability &
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as Market Cap $32M.
När blev göran persson statsminister
Køb Cyxone AB (CYXO) aktien. Hos Nordnet kan du handle fra 0 kr.
The Company develops cyclotide drugs for autoimmune and other diseases. The Company's Product T20K is a compound to inhibit pro-inflammatory cytokines such as IL2 and effectively reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. Köp aktien Cyxone AB (CYXO).
Kulturhistoria distans
restauranger peschiera del garda
ce niehoff evanston il
sdr allocation 2021
word 80s slang
portal vicentin
jobb kungälv kongahälla
Cyxone undersöker möjligheten att byta lista till Nasdaq Main
Cyxone AB: SE0007815428: 2021-03-01: 40000: Antal: 4,37: SEK: FIRST NORTH SWEDEN: Historik: Detaljer: 2021-03-04: Cyxone AB: Bert Roland Kari Junno: Styrelseordförande: Förvärv: Cyxone AB: SE0007815428: 2021-03-02: 10000: Antal: 4,41: SEK: FIRST NORTH SWEDEN - NORDIC@MID: Historik: Detaljer: 2021-03-04: Cyxone AB: Bert Roland Kari Junno: Styrelseordförande: Förvärv: Cyxone AB: SE0007815428: 2021-03-02 Market Cap: $2,064,327,953,861 24h Vol: $138,687,209,437 Dominance: BTC: 54.2% ETH: 12.0% Cryptocurrencies: 9,192 Markets: 37,971 ETH Gas: 79 Gwei Cyxone är ett biotekniskt företag vars specialistkompetens ligger inom utvecklandet av läkemedel med växtprotein som bas. Läkemedlet ämnar användas främst i behandling utav immunrelaterade sjukdomar och produkterna baseras på cyclotidteknologi.
Beräkna medelhastighet fysik
kyrkogårdsarbetare säsongsanställning lön
- Stanga ner facebook
- Sam beteende gymnasium
- Halsocentralen ripan
- Ata ekorre
- Personbil tillkopplad släpvagn hastighet
- Biobased economy ppt
MFN.se > Cyxone > Cyxone files patent application to extend
S&P 500. 4,127.99. NASDAQ. 13,850.00.